Maas Fiona, Spoorenberg Anneke, Brouwer Elisabeth, van der Veer Eveline, Bootsma Hendrika, Bos Reinhard, Wink Freke R, Arends Suzanne
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Semin Arthritis Rheum. 2017 Apr;46(5):562-568. doi: 10.1016/j.semarthrit.2016.11.003. Epub 2016 Nov 9.
To investigate radiographic damage and 4-year progression of the cervical facet joints in a prospective observational cohort of AS patients treated with TNF-α inhibitors, to compare this with damage and progression of the cervical vertebral bodies, and to study the relation with patient characteristics and clinical outcome.
Patients from the Groningen Leeuwarden AS (GLAS) cohort starting TNF-α inhibitors with baseline and 4-year radiographs were included. Cervical facet joints and vertebral bodies were scored by two independent readers according to the method of de Vlam and mSASSS, respectively.
At baseline, 25 of 99 (25%) AS patients had partial or complete ankylosis of the cervical facet joints, whereas 51 (52%) patients had non-bridging or bridging syndesmophytes of cervical vertebral bodies. During 4 years, 13 (13%) patients developed new (partial) ankylosis of the facet joints, whereas 26 (26%) developed new (bridging) syndesmophytes. Facet joint damage and progression without involvement of the vertebral bodies were seen in 5 (5%) and 8 (8%) patients, respectively. Damage of facet joints was associated with longer disease duration, history of IBD/uveitis/psoriasis, higher disease activity, larger occiput-to-wall distance, higher mSASSS, and presence of syndesmophytes. Progression of the facet joints was associated with larger occiput-to-wall distance and more facet joint damage at baseline.
Cervical facet joints were frequently involved in AS. During 4 years of TNF-α blocking therapy, 13% of the patients showed radiographic progression of cervical facet joints of which the majority did not show progression of vertebral bodies.
在接受肿瘤坏死因子-α抑制剂治疗的强直性脊柱炎(AS)患者前瞻性观察队列中,研究颈椎小关节的影像学损伤及4年进展情况,将其与颈椎椎体的损伤和进展进行比较,并研究其与患者特征及临床结局的关系。
纳入格罗宁根-吕伐登AS(GLAS)队列中开始使用肿瘤坏死因子-α抑制剂且有基线和4年X线片的患者。颈椎小关节和椎体分别由两名独立阅片者根据德弗拉姆方法和改良斯托克强直性脊柱炎脊柱评分(mSASSS)进行评分。
基线时,99例AS患者中有25例(25%)颈椎小关节存在部分或完全强直,而51例(52%)患者颈椎椎体有非桥接或桥接骨桥形成。在4年期间,13例(13%)患者出现新的(部分)小关节强直,26例(26%)出现新的(桥接)骨桥形成。分别有5例(5%)和8例(8%)患者出现未累及椎体的小关节损伤和进展。小关节损伤与病程较长、炎症性肠病/葡萄膜炎/银屑病病史、疾病活动度较高、枕墙距较大、mSASSS较高以及骨桥形成有关。小关节进展与枕墙距较大及基线时更多的小关节损伤有关。
颈椎小关节在AS中常受累。在4年的肿瘤坏死因子-α阻断治疗期间,13%的患者颈椎小关节出现影像学进展,其中大多数患者椎体未出现进展。